메뉴 건너뛰기




Volumn 12, Issue 3, 2008, Pages 507-528

Tailored Treatment for Hepatitis C

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

EID: 46749121770     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.03.011     Document Type: Review
Times cited : (19)

References (36)
  • 1
    • 0242456086 scopus 로고    scopus 로고
    • Scope of worldwide hepatitis C problem
    • Brown R.S., and Gaglio J.P. Scope of worldwide hepatitis C problem. Liver Transpl 9 11 (2003) S10-S13
    • (2003) Liver Transpl , vol.9 , Issue.11
    • Brown, R.S.1    Gaglio, J.P.2
  • 2
    • 1442308277 scopus 로고    scopus 로고
    • Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
    • Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med 140 5 (2004) 370-381
    • (2004) Ann Intern Med , vol.140 , Issue.5 , pp. 370-381
    • Zeuzem, S.1
  • 3
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial
    • Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 9286 (2001) 958-965
    • (2001) Lancet , vol.358 , Issue.9286 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3
  • 4
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 13 (2002) 975-982
    • (2002) N Engl J Med , vol.347 , Issue.13 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 5
    • 0034619946 scopus 로고    scopus 로고
    • Peginterferon alfa-2a in patients with chronic hepatitis C
    • Zeuzem S., Feinmann S.V., Rasenack J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343 23 (2000) 1666-1672
    • (2000) N Engl J Med , vol.343 , Issue.23 , pp. 1666-1672
    • Zeuzem, S.1    Feinmann, S.V.2    Rasenack, J.3
  • 6
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alfa-2a plus ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose
    • Hadziyannis S., Sette Jr. H., Morgan T.R., et al. Peginterferon-alfa-2a plus ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 40 5 (2004) 346-355
    • (2004) Ann Intern Med , vol.40 , Issue.5 , pp. 346-355
    • Hadziyannis, S.1    Sette Jr., H.2    Morgan, T.R.3
  • 7
    • 0037371144 scopus 로고    scopus 로고
    • Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
    • Berg T., Sarrazin C., Herrmann E., et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37 3 (2003) 600-609
    • (2003) Hepatology , vol.37 , Issue.3 , pp. 600-609
    • Berg, T.1    Sarrazin, C.2    Herrmann, E.3
  • 8
    • 23444460553 scopus 로고    scopus 로고
    • Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    • Ferenci P., Fried M.W., Shiffman M.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43 3 (2005) 425-433
    • (2005) J Hepatol , vol.43 , Issue.3 , pp. 425-433
    • Ferenci, P.1    Fried, M.W.2    Shiffman, M.L.3
  • 9
    • 0031924165 scopus 로고    scopus 로고
    • Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
    • Zeuzem S., Lee J.H., Franke A., et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 27 (1998) 1149-1156
    • (1998) Hepatology , vol.27 , pp. 1149-1156
    • Zeuzem, S.1    Lee, J.H.2    Franke, A.3
  • 10
    • 0041822106 scopus 로고    scopus 로고
    • Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    • Davis G.L., Wong J.B., McHutchison J., et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 3 (2003) 645-652
    • (2003) Hepatology , vol.38 , Issue.3 , pp. 645-652
    • Davis, G.L.1    Wong, J.B.2    McHutchison, J.3
  • 11
    • 0033802570 scopus 로고    scopus 로고
    • Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays
    • Sarrazin C., Teuber G., Kokka R., et al. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 32 4 Pt 1 (2000) 818-823
    • (2000) Hepatology , vol.32 , Issue.4 PART 1 , pp. 818-823
    • Sarrazin, C.1    Teuber, G.2    Kokka, R.3
  • 12
    • 33747048398 scopus 로고    scopus 로고
    • HCV RNA detection by TMA during the Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
    • HALT-C Trial Group
    • Morishima C., Morgan T.R., Everhart J.E., et al., HALT-C Trial Group. HCV RNA detection by TMA during the Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 44 2 (2006) 360-367
    • (2006) Hepatology , vol.44 , Issue.2 , pp. 360-367
    • Morishima, C.1    Morgan, T.R.2    Everhart, J.E.3
  • 13
    • 30044437827 scopus 로고    scopus 로고
    • American Gastroenterological Association medical position statement on the management of hepatitis C
    • Dienstag J.L., and McHutchison J.G. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 130 1 (2006) 225-230
    • (2006) Gastroenterology , vol.130 , Issue.1 , pp. 225-230
    • Dienstag, J.L.1    McHutchison, J.G.2
  • 14
    • 1842479859 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C
    • Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 4 (2004) 1147-1171
    • (2004) Hepatology , vol.39 , Issue.4 , pp. 1147-1171
    • Strader, D.B.1    Wright, T.2    Thomas, D.L.3
  • 15
    • 28844451934 scopus 로고    scopus 로고
    • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    • Zeuzem S., Buti M., Ferenci P., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44 1 (2006) 97-103
    • (2006) J Hepatol , vol.44 , Issue.1 , pp. 97-103
    • Zeuzem, S.1    Buti, M.2    Ferenci, P.3
  • 16
    • 33646590308 scopus 로고    scopus 로고
    • Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    • Jensen D.M., Morgan T.R., Marcellin P., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43 5 (2006) 954-960
    • (2006) Hepatology , vol.43 , Issue.5 , pp. 954-960
    • Jensen, D.M.1    Morgan, T.R.2    Marcellin, P.3
  • 17
    • 34250881946 scopus 로고    scopus 로고
    • 24 Week treatment regimen with peginterferon-alpha-2a (40 KD) (Pegasys) plus ribavirin (Copegus) in HCV genotype 1 or 4 'super-responders.'
    • Ferenci P., Bergholz U., Laferl H., et al. 24 Week treatment regimen with peginterferon-alpha-2a (40 KD) (Pegasys) plus ribavirin (Copegus) in HCV genotype 1 or 4 'super-responders.'. J Hepatol 44 Suppl 2 (2006) S6
    • (2006) J Hepatol , vol.44 , Issue.SUPPL. 2
    • Ferenci, P.1    Bergholz, U.2    Laferl, H.3
  • 18
    • 21844477610 scopus 로고    scopus 로고
    • International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
    • Zeuzem S., Pawlotsky J.M., Lukasiewicz E., et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 43 2 (2005) 250-257
    • (2005) J Hepatol , vol.43 , Issue.2 , pp. 250-257
    • Zeuzem, S.1    Pawlotsky, J.M.2    Lukasiewicz, E.3
  • 19
    • 46749103460 scopus 로고    scopus 로고
    • Evaluation of the efficacy of an 18 week short treatment duration in HCV type 1 infected patients based upon early viral kinetics: an approach to recognise "super-responders."
    • Berg T., Weich V., Teuber G., et al. Evaluation of the efficacy of an 18 week short treatment duration in HCV type 1 infected patients based upon early viral kinetics: an approach to recognise "super-responders.". Hepatology 44 Suppl 1 (2006) 319A
    • (2006) Hepatology , vol.44 , Issue.SUPPL. 1
    • Berg, T.1    Weich, V.2    Teuber, G.3
  • 20
    • 34447644163 scopus 로고    scopus 로고
    • Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2A (40 KD) (Pegasys) plus ribavirin (Copegus)
    • Zeuzem S., Fried M.W., Reddy K.R., et al. Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2A (40 KD) (Pegasys) plus ribavirin (Copegus). Hepatology 44 Suppl 1 (2006) 267A
    • (2006) Hepatology , vol.44 , Issue.SUPPL. 1
    • Zeuzem, S.1    Fried, M.W.2    Reddy, K.R.3
  • 21
    • 46749085258 scopus 로고    scopus 로고
    • Better prediction of SVR in patients with HCV genotype 1 (G1) with peginterferon alfa-2a (Pegasys) plus ribavirin: improving differentiation between low (lvl) and high baseline viral load (hvl)
    • Zehnter E., Mauss S., John C., et al. Better prediction of SVR in patients with HCV genotype 1 (G1) with peginterferon alfa-2a (Pegasys) plus ribavirin: improving differentiation between low (lvl) and high baseline viral load (hvl). Hepatology 44 Suppl 1 (2006) 328A
    • (2006) Hepatology , vol.44 , Issue.SUPPL. 1
    • Zehnter, E.1    Mauss, S.2    John, C.3
  • 22
    • 34548017344 scopus 로고    scopus 로고
    • Definition of a pre-treatment viral load cut-off for an optimized prediction of treatment outcome in patients with genotype 1 infection receiving either 48 or 72 weeks of peginterferon alfa-2a plus ribavirin
    • Berg T., von Wagner M., Hinrichsen H., et al. Definition of a pre-treatment viral load cut-off for an optimized prediction of treatment outcome in patients with genotype 1 infection receiving either 48 or 72 weeks of peginterferon alfa-2a plus ribavirin. Hepatology 44 Suppl 1 (2006) 321A
    • (2006) Hepatology , vol.44 , Issue.SUPPL. 1
    • Berg, T.1    von Wagner, M.2    Hinrichsen, H.3
  • 23
    • 0038035716 scopus 로고    scopus 로고
    • Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases
    • Buti M., Valdez A., Sanchez-Avila F., et al. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 37 5 (2003) 1226-1227
    • (2003) Hepatology , vol.37 , Issue.5 , pp. 1226-1227
    • Buti, M.1    Valdez, A.2    Sanchez-Avila, F.3
  • 24
    • 33645992473 scopus 로고    scopus 로고
    • Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
    • Berg T., von Wagner M., Nasser S., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 4 (2006) 1086-1097
    • (2006) Gastroenterology , vol.130 , Issue.4 , pp. 1086-1097
    • Berg, T.1    von Wagner, M.2    Nasser, S.3
  • 25
    • 33746564989 scopus 로고    scopus 로고
    • Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
    • TeraViC-4 Study Group
    • Sanchez-Tapias J.M., Diago M., Escartin P., et al., TeraViC-4 Study Group. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131 2 (2006) 451-460
    • (2006) Gastroenterology , vol.131 , Issue.2 , pp. 451-460
    • Sanchez-Tapias, J.M.1    Diago, M.2    Escartin, P.3
  • 26
    • 37749051824 scopus 로고    scopus 로고
    • Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders
    • Pearlman B.L., Ehleben C., and Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 46 6 (2007) 1688-1694
    • (2007) Hepatology , vol.46 , Issue.6 , pp. 1688-1694
    • Pearlman, B.L.1    Ehleben, C.2    Saifee, S.3
  • 27
    • 34250896579 scopus 로고    scopus 로고
    • Customizing treatment with peginterferon alfa-2a (40 KD) (Pegasys) plus ribavirin (Copegus) in patients with HCV genotype 1 or 4 infection, interim results of a prospective randomized trial
    • Ferenci P., Laferl H., Scherzer T.-M., et al. Customizing treatment with peginterferon alfa-2a (40 KD) (Pegasys) plus ribavirin (Copegus) in patients with HCV genotype 1 or 4 infection, interim results of a prospective randomized trial. Hepatology 44 Suppl 1 (2006) 336A
    • (2006) Hepatology , vol.44 , Issue.SUPPL. 1
    • Ferenci, P.1    Laferl, H.2    Scherzer, T.-M.3
  • 28
    • 1642328395 scopus 로고    scopus 로고
    • A 48-week duration of therapy with pegylated interferon-alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus
    • Drusano G.L., and Preston S.L. A 48-week duration of therapy with pegylated interferon-alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 189 (2004) 964-970
    • (2004) J Infect Dis , vol.189 , pp. 964-970
    • Drusano, G.L.1    Preston, S.L.2
  • 29
    • 2442683905 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3
    • Zeuzem S., Hultcrantz R., Bourliere M., et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol 40 6 (2004) 993-999
    • (2004) J Hepatol , vol.40 , Issue.6 , pp. 993-999
    • Zeuzem, S.1    Hultcrantz, R.2    Bourliere, M.3
  • 30
    • 0033914625 scopus 로고    scopus 로고
    • Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus
    • Neumann A.U., Lam N.P., Dahari H., et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182 (2000) 28-35
    • (2000) J Infect Dis , vol.182 , pp. 28-35
    • Neumann, A.U.1    Lam, N.P.2    Dahari, H.3
  • 31
    • 10644264391 scopus 로고    scopus 로고
    • Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
    • Dalgard O., Bjoro K., Hellum K.B., et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40 6 (2004) 1260-1265
    • (2004) Hepatology , vol.40 , Issue.6 , pp. 1260-1265
    • Dalgard, O.1    Bjoro, K.2    Hellum, K.B.3
  • 32
    • 20544443172 scopus 로고    scopus 로고
    • Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
    • Mangia A., Santoro R., Minerva N., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352 25 (2005) 2609-2617
    • (2005) N Engl J Med , vol.352 , Issue.25 , pp. 2609-2617
    • Mangia, A.1    Santoro, R.2    Minerva, N.3
  • 33
    • 23244457832 scopus 로고    scopus 로고
    • Randomized multicenter study comparing 16 vs. 24 weeks of combination therapy with peginterferon alfa-2a plus ribavirin in patients chronically infected with HCV genotype 2 or 3
    • von Wagner M., Huber M., Berg T., et al. Randomized multicenter study comparing 16 vs. 24 weeks of combination therapy with peginterferon alfa-2a plus ribavirin in patients chronically infected with HCV genotype 2 or 3. Gastroenterology 129 2 (2005) 522-527
    • (2005) Gastroenterology , vol.129 , Issue.2 , pp. 522-527
    • von Wagner, M.1    Huber, M.2    Berg, T.3
  • 34
    • 34147207791 scopus 로고    scopus 로고
    • A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
    • Yu M.L., Dai C.Y., Huang J.F., et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56 4 (2007) 553-559
    • (2007) Gut , vol.56 , Issue.4 , pp. 553-559
    • Yu, M.L.1    Dai, C.Y.2    Huang, J.F.3
  • 35
    • 34447318385 scopus 로고    scopus 로고
    • Peginterferon alfa-2A and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
    • Shiffman M.L., Suter F., Bacon B., et al. Peginterferon alfa-2A and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357 2 (2007) 124-134
    • (2007) N Engl J Med , vol.357 , Issue.2 , pp. 124-134
    • Shiffman, M.L.1    Suter, F.2    Bacon, B.3
  • 36
    • 34250852697 scopus 로고    scopus 로고
    • Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virologic response?
    • [abstract no. 8]
    • Willems B., Hadziyannis S.J., Morgan T.R., et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virologic response?. J Hepatol 46 Suppl 1 (2007) S6 [abstract no. 8]
    • (2007) J Hepatol , vol.46 , Issue.SUPPL. 1
    • Willems, B.1    Hadziyannis, S.J.2    Morgan, T.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.